Royalty Pharma plc Class A (RPRX)
BiotechSign Signal Grade
Composite of clinical trial activity, dilution exposure, publications, short interest, and insider transactions — all from verified public filings.
Pipeline Overview
- Therapeutic Focus
- Biotech / Pharmasrc
Clinical Trial Activity
(ClinicalTrials.gov aggregate)
ClinicalTrials.gov aggregate as of 2026-10-13. ClinicalTrials.gov
Dilution Risk
LOW DILUTION RISKDilution score: 10/100 (LOW), cash runway not available
Derived from verified regulatory filings. Measures dilution exposure from warrants, convertibles, and offering history. DilutionWatch SEC-derived score
Short Interest
Short interest: ?% of float, squeeze risk: MODERATE
FINRA short sale data. FINRA short interest
Upcoming Catalysts
Recent News & SEC Filings
- Royalty Pharma declares fourth quarter 2026 dividend
- Royalty Pharma (RPRX) Offers Attractive Risk-Reward Profiles at Reasonable Multiples
- Royalty Pharma to announce third quarter 2026 financial results on November 4, 2026
- Why Royalty Pharma (RPRX) is Poised to Beat Earnings Estimates Again
- Royalty Pharma Owns a Piece of 16 Blockbuster Drugs -- Is the Stock a Buy?
- Royalty Pharma Eyes AI, China Growth While Navigating Biopharma Policy Shifts
- Royalty Pharma (RPRX) Stock Looks Richly Priced After Its 136% Run
- Royalty Pharma (RPRX) Could Be 10% Undervalued As Conference Spotlight Returns
Headlines from public sources. BiotechSign does not endorse or verify linked content.
Get real-time catalyst alerts, analyst signals, dilution risk tracking, and full pipeline data for Royalty Pharma plc Class A.
Full RPRX Dashboard Sign Up FreePrimary Sources
This page reports only records present in the BiotechSign source payload as of the generation date. It does not infer drug efficacy, clinical outcome probability, approval odds, revenue, market size, or unreported regulatory events.